Response to "Systemic Bevacizumab for Hereditary Hemorrhagic Telangiectasia: Considerations from Observational Studies"

Otolaryngol Head Neck Surg. 2019 Feb;160(2):369-370. doi: 10.1177/0194599818813522.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Angiogenesis Inhibitors
  • Bevacizumab
  • Epistaxis
  • Humans
  • Telangiectasia, Hereditary Hemorrhagic*
  • Treatment Outcome

Substances

  • Angiogenesis Inhibitors
  • Bevacizumab